Vifor Pharma Group announced that Abbas Hussain will take over as CEO of the company on August 16, 2021, Succeeding Stefan Schulze, who has decided to step down and leave the company for personal reasons. Abbas Hussain (56, British citizen) has a successful and international career of more than 30 years as an executive in the healthcare sector. From 2008 to 2017, Abbas Hussain held various leadership positions for the British pharmaceutical group GlaxoSmithKline, most recently as Global President Pharmaceuticals and Vaccines for five years. Prior to that, he worked for 20 years for the U.S. pharmaceutical group Eli Lilly, holding management positions at sites in the US, Europe, Asia and Australia. In recent years, he has contributed his experience as an independent member of the boards of directors of major pharmaceutical, biotech and medical device companies, such as Teva Pharmaceuticals, CSL and Cochlear. He has also acted as an advisor to private equity and venture capital firms focused on the healthcare sector. Until Abbas Hussain joins the company on August 16, 2021, Stefan Schulze will continue to have overall executive responsibility for the Vifor Pharma Group.